Therapeutic Advances in Neurological Disorders · 2023 · 12 citations · 30 references
Life SciencesImmunologyPharmacotherapyImmunotherapyMonoclonal AntibodiesRheumatologyMonoclonal Antibody TherapyMultiple SclerosisMultiple Sclerosis PharmacotherapyTherapeutic Monoclonal AntibodiesAutoimmune Adverse EventsAutoimmune ComorbidityCase-control Study DesignMultiple Sclerosis TherapyPediatric Multiple Sclerosis TreatmentRelapse TreatmentRelapsing-remitting Multiple Sclerosis TreatmentTherapeutic Switching
Background: Paediatric-onset multiple sclerosis (POMS) therapeutic approach derives from of adult-onset multiple sclerosis (AOMS) tailored algorithms. Objectives: To evaluate in a common clinical scenario the efficacy and safety of alemtuzumab (ALZ) in POMS and AOMS. Methods: All patients switching from natalizumab (NTZ) to ALZ for safety concerns (high anti-John Cunningham Virus Antibody Index value, anti-JCV Index) were enrolled in this single-centre, retrospective, case-control open-label study. Results: Ten POMS and 27 AOMS were followed up for 51.3 months. After month 12, we found a lower risk of clinical or radiological relapses among AOMS patients and among patients with older age at ALZ (both p < 0.05). Survival analysis revealed an increased risk of relapse in POMS compared with AOMS (logrank p = 0.00498) and patients starting ALZ before age 22.75 years than the elder ones (logrank p = 0.0018). Survival analysis did not disclose any difference between AOMS and POMS (logrank p = 0.27) in terms of progression independent of any relapse activity (PIRA). In addition, no evidence of relapse-associated worsening was observed. Autoimmune events were reported by 5 AOMS and no POMS (29.4% versus 0.0%, p = 0.057), and survival analysis was not significant (logrank p = 0.0786). Conclusion: ALZ seems more effective in AOMS than in POMS following NTZ. These findings underrate ALZ effectiveness when shifting from NTZ in POMS.
30
How patients with multiple sclerosis acquire disability
Fred Lublin, Dieter A. Häring, Habib Ganjgahi et al. · Brain · 2022 · 528 citations · Full text
Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis
Ivan Jelčić, Faiez Al Nimer, Jian Wang et al. · Cell · 2018 · 519 citations · Full text
Life Sciences, Immunology, Neurology +17
Defining reliable disability outcomes in multiple sclerosis
Tomáš Kalinčík, Gary Cutter, Tim Spelman et al. · Brain · 2015 · 243 citations · Full text